Single-Use Technology for Biopharmaceuticals Market to Reach USD 652.44 Billion by 2034 at 42.11% CAGR

The single-use technology for biopharmaceuticals market is positioned for rapid expansion as drug developers and contract manufacturers adopt disposable processing equipment to make production more flexible. Polaris Market Research reports that the market was valued at USD 18.61 billion in 2025, is estimated at USD 27.61 billion in 2026, and is projected to reach USD 652.44 billion by 2034, registering a CAGR of 42.11% from 2026 to 2034. The market covers disposable bioreactors, bags, filters, tubing, connectors and assemblies used in biologics manufacturing.

Single-Use Technology for Biopharmaceuticals Market Growth and Industry Outlook

Expansion is propelled by wider use of disposable bioprocessing systems, greater demand for flexible biologics manufacturing, increasing capacity at contract development and manufacturing organizations, and the need to simplify production changeovers. Manufacturers use preassembled components for individual runs instead of repeatedly cleaning and sterilizing fixed equipment, which supports multi-product operations. Polaris Market Research’s comparison with reusable systems reports upfront capital that is 50–66% lower and labor requirements that are 30–50% lower for single-use systems, while recurring cost per batch is higher because bags, tubing and filters are replaced each time.

Key Market Drivers and Emerging Trends

Regulation is a defining driver. USP General Chapter <665> was implemented in May 2026 to standardize extraction procedures for plastics used in pharmaceutical manufacturing, and USP <1665> offers a risk-based approach for assessing single-use components. Clearer expectations for extractables and leachables testing give buyers a firmer reference point, although validation and testing requirements can raise adoption costs, particularly for smaller suppliers. Polaris Market Research rates this a high-impact driver over the short term, from 2026 to 2028, with North America and Europe the most affected regions.

Consolidation is another theme. In February 2025, Thermo Fisher Scientific announced an agreement to acquire Solventum’s Purification & Filtration business for approximately USD 4.1 billion in cash, underscoring the strategic weight of downstream filtration systems. On the technology side, gamma-stable polymers and sensors that report pH, dissolved oxygen and pressure within closed systems are moving deeper into disposable workflows.

Segment and Application Insights

Single-use bioreactors held the largest product share at 38.42% in 2025 because of their central role in upstream production and recurring consumable needs. Filtration systems are projected to grow at a 43.17% CAGR as downstream processing capabilities expand. By application, monoclonal antibodies held a 40.84% share in 2025, while the cell & gene therapy application is expected to record the highest CAGR at 49.86%. Among end users, biopharmaceutical manufacturers held 54.12% of the market in 2025, and contract development and manufacturing organizations and CROs are forecast to grow at a 46.92% CAGR as outsourcing increases.

Regional Market Perspective

North America held the leading share of 34.62% in 2025, supported by an established biopharmaceutical manufacturing base, strong research activity and a mature supplier ecosystem. Europe accounted for 28.16% of the market, Latin America for 6.42% and the Middle East and Africa for 5.32%. Asia Pacific is projected to record the highest CAGR at 47.83%, driven by expanding capacity across China, India, South Korea and Singapore. India’s biopharma SHAKTI initiative adds to that momentum, with proposed funding of about USD 1.05 billion over five years.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/single-use-technology-for-biopharmaceuticals-market

Competitive Landscape

The competitive environment combines a limited number of large, vertically integrated suppliers with specialty component manufacturers. Sartorius AG, Thermo Fisher Scientific, Danaher Corporation through Cytiva/Pall and Merck KGaA through MilliporeSigma offer broad portfolios, while Enpro and Avantor provide more specialized components and assemblies. In July 2026, Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, a supplier of cell processing and biopreservation tools for the cell and gene therapy market, at a total enterprise value of approximately USD 1.5 billion. Sartorius also extended ISCC Plus certification to two sites in January 2026, making bio-circular filters and additional single-use fluid management technologies available. Competition increasingly centers on breadth, validation capability, supply reliability and the ability to integrate components into a qualified workflow.

Future Market Outlook

The outlook for the single-use technology for biopharmaceuticals market over the next three to five years is likely to be shaped by supplier consolidation in filtration and purification, government-backed infrastructure in emerging hubs, and compliance-driven standardization following USP <665> and <1665>. Smaller vendors without extractables and leachables testing infrastructure could face more qualification pressure, which may benefit larger integrated suppliers in the near term. With single-use bioreactors, filtration systems and monoclonal antibodies production anchoring demand, and biologics manufacturing capacity expanding, Polaris Market Research projects the market to reach USD 652.44 billion by 2034.

More Trending Latest Reports By Polaris Market Research:

Terminal Tractor Market

Advanced Ceramics Market

Polyurethane Sealants Market

Power Factor Correction Market

Advanced Ceramics Market

Connected Car Market

Unsaturated Polyester Resins Market

Automotive E-Compressor Market

Benign Prostatic Hyperplasia Surgical Treatment Market